Capital World Investors Cellectis S.A. Transaction History

Capital World Investors

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.39 - $4.93 $886,845 - $1.83 Million	-371,065 Reduced 59.75%	250,000 $708,000
Q1 2022 May 16, 2022	SELL	$3.45 - $8.77 $876,075 - $2.23 Million	-253,935 Reduced 29.02%	621,065 $2.82 Million
Q2 2018 Aug 14, 2018	BUY	$27.78 - $38.53 $24.3 Million - $33.7 Million	875,000 New	875,000 $24.8 Million

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.